The latest update is out from Acumen Pharmaceuticals ( (ABOS) ).
On March 27, 2025, Acumen Pharmaceuticals announced the completion of enrollment for its ALTITUDE-AD Phase 2 study, investigating sabirnetug for early Alzheimer’s disease, with topline results expected in late 2026. The company reported a cash balance of $231.5 million as of December 31, 2024, projected to support operations into the first half of 2027, despite a net loss of $102.3 million for 2024 due to increased R&D expenses.
More about Acumen Pharmaceuticals
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease. The company is advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody, in its ongoing Phase 2 clinical trial ALTITUDE-AD for early symptomatic Alzheimer’s disease patients.
YTD Price Performance: -37.30%
Average Trading Volume: 256,578
Technical Sentiment Signal: Buy
Current Market Cap: $69.69M
See more insights into ABOS stock on TipRanks’ Stock Analysis page.